NEURIX in a European consortium focusing on neuroinflammation

The role of NEURIX within NEURINOX, the European FP7 consortium, consists in developing human in vitro models of neuroinflammation as drug-efficacy screening platforms. These models, generated from induced pluripotent stem cells (iPSCs), will be used as alternative human platforms to screen compounds (e.g. NOX inhibitors) provided by NEURINOX partners: The first model will be in 2D while the second platform will present a 3D brain-like structure. Thus, NEURINOX compounds will get unique additional value thanks to direct indication of their neurotoxicity and efficacy against neuroinflammation on human tissue at an early stage in their development process.